The pilot project is fully aligned with Lumito’s strategy to collaborate with established and specialised CRO companies as well as stakeholders within the tissue analysis field, to explore potential applications of the Company’s technology. By combining complementary technologies and expertise, the parties intend to evaluate possible synergies and the potential value of an integrated solution. The project is also supported by an external scientific expert in pathology, who contributes advisory support and specialist expertise.

“We are pleased to have initiated this collaboration with OracleBio, a CRO company highly specialised in analysis of digital tissue images. The pilot project gives us the opportunity to, at an early stage, explore how our respective strengths can be combined to create value in drug development”, says Sanna Wallenborg, CEO of Lumito.

“At OracleBio, we are seeing an increasing demand from Pharma clients for more detailed histological profiling of novel therapeutic targets at the tissue, cell and cell compartment level. Combining our image analysis expertise with high quality histological staining and imaging techniques enables us to provide an optimal service to our clients. By collaborating with Lumito, we gain the opportunity to work with an innovative tissue imaging technology and look forward to jointly evaluating potential applications”, says Lorcan Sherry, CSO at OracleBio.

The pilot project aims to evaluate potential future opportunities and, at this stage, does not include any financial or commercial commitments beyond the execution of the project.